Bilirubin Derivative Ultrasound Contrast Agent for Stable Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ultrasound contrast agents face challenges in maintaining stability within the bloodstream due to temperature and pressure changes, and in effectively treating lesions while providing diagnostic imaging, as they tend to burst and are not immune system compatible.
Innovation Solution
Development of a fine particle with a hydrophobic gas core and a shell comprising a bilirubin derivative that is amphiphilic, allowing it to react with reactive oxygen species and load metals like iron oxide nanoparticles, enhancing stability and immune system compatibility, and enabling both diagnostic imaging and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Illumination intensity
If conventional ultrasound contrast agents are used, then image signal enhancement is achieved, but the bubbles burst due to temperature and pressure changes
Solution Approach 1:
The patent uses a phospholipid bilayer shell to encapsulate the gas core, creating a flexible yet stable structure that can withstand temperature and pressure changes in the bloodstream. The phospholipid molecules form a protective membrane that maintains bubble integrity while allowing the bubble to resonate with ultrasound waves, thus resolving the contradiction between signal enhancement and stability.
Solution Approach 2:
The contrast agent employs a composite structure combining hydrophobic gas core with amphiphilic phospholipid shell. This composite material design allows the hydrophobic interior to maintain gas integrity while the hydrophilic exterior interacts favorably with the aqueous bloodstream environment, preventing bubble rupture and improving reliability.
2Measurement precision
If conventional ultrasound contrast agents are used, then diagnostic imaging is improved, but they are not compatible with the immune system
Solution Approach 1:
The phospholipid bilayer shell mimics natural cell membrane structures, making the contrast agent biocompatible and less recognizable to the immune system. This biological mimicry allows the agent to circulate in the bloodstream without triggering immune responses, while still providing excellent ultrasound imaging properties.
3Strength
If hydrophobic molecules are used for the shell, then contact with gas core is improved, but stability in aqueous environment deteriorates
Solution Approach 1:
The patent changes the chemical parameters of the shell material by using amphiphilic phospholipids that have both hydrophobic and hydrophilic regions. The hydrophobic tails contact the gas core providing strong adhesion, while the hydrophilic heads face the aqueous bloodstream providing stability. This dual-nature parameter change resolves the contradiction between core contact and environmental stability.
Solution Approach 2:
The phospholipid molecules act as composite materials with distinct hydrophobic and hydrophilic regions. This molecular-level composite structure allows simultaneous optimization of both core contact (via hydrophobic region) and aqueous stability (via hydrophilic region), eliminating the trade-off between these two requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bilirubin derivative-based ultrasound contrast agent provides stable imaging and therapeutic capabilities by maintaining bubble integrity, reacting with ROS for enhanced imaging and treating lesions, while also serving as a carrier for drugs and being sensitive to magnetic resonance, thus addressing the limitations of existing agents.
Implementation Method 1
the bilirubin derivative shell reacts sensitively to reactive oxygen species (ROS)
Implementation Method 2
When the gaseous bubble of the ultrasound contrast agent enters the bloodstream, which is an aqueous environment, and is exposed to ultrasound, resonance and ultrasound dispersion occurs
Implementation Method 3
an amphiphilic bilirubin derivative, prepared by introducing a hydrophilic molecule into bilirubin, can be used to form a shell of the ultrasound contrast agent particles with a hydrophobic gas core
Implementation Method 4
can effectively load or chelate such metals as iron oxide nanoparticles
Data Source
AI summary
Provided is a bilirubin derivative-based ultrasound contrast agent for diagnosis and treatment. The fine particles including the bilirubin derivative are sensitive to reactive oxygen species (ROS), bind with hydrophobic drugs, and can effectively chelate metals such as iron oxide nanoparticles. Therefore, the fine particle of the present invention can be used as an ultrasound contrast agent for diagnosis, as a magnetic resonance imaging contrast agent, or as a carrier for hydrophobic drugs or platinum-based drugs.